Loading...

Home
ETF
SNTI

SNTI

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

SNTI News

Senti Bio's SENTI-202 Clinical Data Shows Promising Results

4d agoNewsfilter

Senti Biosciences Grants New Employee 13,680 Stock Options at $1.31 Each

Dec 18 2025Globenewswire

Senti Biosciences Grants New Employee 13,680 Stock Options at $1.31 Each

Dec 18 2025Newsfilter

Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers

Dec 10 2025NASDAQ.COM

What’s Causing the Decline in Senti Bio Stock Focused on Gene Therapy Today?

Dec 09 2025Benzinga

Senti Biosciences Obtains FDA RMAT Designation for SENTI-202

Dec 09 2025NASDAQ.COM

Senti Bio Receives FDA RMAT Designation for SENTI-202, Demonstrating Significant Efficacy

Dec 09 2025Newsfilter

Senti Bio Reports 50% Efficacy for SENTI-202 in R/R AML Patients

Dec 09 2025Newsfilter

Senti Reports Encouraging Phase 1 Results for SENTI-202 in Relapsed/Refractory AML

Dec 09 2025NASDAQ.COM

Repare Surges 30%, Nuvalent Rises 9% in After-Hours Biotech Gains

Nov 17 2025NASDAQ.COM

Senti Bio to Showcase at Chardan's 9th Annual Genetic Medicines Conference

Oct 16 2025Newsfilter

Senti Bio to Showcase at the MedInvest Biotech & Pharma Conference

Sep 18 2025Newsfilter

Senti Bio to Showcase at the 27th Annual Global Investment Conference Hosted by H.C. Wainwright

Sep 02 2025Newsfilter

Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 12 2025Newsfilter

Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

Aug 08 2025Benzinga

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

Aug 07 2025Newsfilter